ContraFect Corporation [NASDAQ: CFRX] price plunged by -8.10 percent to reach at -$0.37. The company report on March 30, 2021 that ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update.
Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Biomedical Advanced Research and Development Authority (BARDA) contract award provides up to $86.8 million for exebacase Phase 3 development.
A sum of 2110766 shares traded at recent session while its average daily volume was at 1.03M shares. ContraFect Corporation shares reached a high of $4.58 and dropped to a low of $4.11 until finishing in the latest session at $4.20.
Guru’s Opinion on ContraFect Corporation [CFRX]:
Mizuho have made an estimate for ContraFect Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 09, 2020. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on June 09, 2020, representing the official price target for ContraFect Corporation stock.
The Average True Range (ATR) for ContraFect Corporation is set at 0.47 The Price to Book ratio for the last quarter was 6.36, with the Price to Cash per share for the same quarter was set at 1.31.
CFRX Stock Performance Analysis:
ContraFect Corporation [CFRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.25. With this latest performance, CFRX shares dropped by -11.02% in over the last four-week period, additionally sinking by -20.45% over the last 6 months – not to mention a drop of -17.81% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CFRX stock in for the last two-week period is set at 36.37, with the RSI for the last a single of trading hit 32.06, and the three-weeks RSI is set at 39.11 for ContraFect Corporation [CFRX]. The present Moving Average for the last 50 days of trading for this stock 5.37, while it was recorded at 4.63 for the last single week of trading, and 5.53 for the last 200 days.
Insight into ContraFect Corporation Fundamentals:
Return on Total Capital for CFRX is now -192.01, given the latest momentum, and Return on Invested Capital for the company is -163.75. Return on Equity for this stock declined to -199.94, with Return on Assets sitting at -65.38. When it comes to the capital structure of this company, ContraFect Corporation [CFRX] has a Total Debt to Total Equity ratio set at 28.55. Additionally, CFRX Total Debt to Total Capital is recorded at 22.21, with Total Debt to Total Assets ending up at 7.05. Long-Term Debt to Equity for the company is recorded at 23.45, with the Long-Term Debt to Total Capital now at 18.24.
Reflecting on the efficiency of the workforce at the company, ContraFect Corporation [CFRX] managed to generate an average of -$853,202 per employee.ContraFect Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.60 and a Current Ratio set at 11.60.
CFRX Stock EPS
With the latest financial reports released by the company, ContraFect Corporation posted -0.49/share EPS, while the average EPS was predicted by analysts to be reported at -0.62/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CFRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ContraFect Corporation go to 12.70%.
ContraFect Corporation [CFRX] Insider Position Details
There are presently around $70 million, or 46.50% of CFRX stock, in the hands of institutional investors. The top three institutional holders of CFRX stocks are: FEDERATED HERMES, INC. with ownership of 5,297,188, which is approximately 0% of the company’s market cap and around 7.91% of the total institutional ownership; BVF INC/IL, holding 1,600,000 shares of the stock with an approximate value of $6.72 million in CFRX stocks shares; and BLACKROCK INC., currently with $6.66 million in CFRX stock with ownership of nearly -1.271% of the company’s market capitalization.
Positions in ContraFect Corporation stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 28 institutional holders increased their position in ContraFect Corporation [NASDAQ:CFRX] by around 2,273,804 shares. Additionally, 21 investors decreased positions by around 1,225,465 shares, while 19 investors held positions by with 13,236,211 shares. The mentioned changes placed institutional holdings at 16,735,480 shares, according to the latest SEC report filing. CFRX stock had 8 new institutional investments in for a total of 1,273,301 shares, while 6 institutional investors sold positions of 927,958 shares during the same period.